Independent Statistician Access

Why the Statistician’s Access Must Be Deliberate

An independent statistician may need interim data to carry out an adaptation analysis, yet the information required for that calculation can reveal more than the trial team should know while the study is ongoing. The central design question is therefore not simply whether the statistician is “blinded.” It is which data, treatment codes, and code key the statistician can access; what analyses they are assigned to perform; and which results they may communicate.

“Independent” describes a functional separation from trial decisions and conduct that could be influenced by interim results. It does not, by itself, specify the statistician’s employer or guarantee that access is appropriately restricted. The role must be defined in the trial’s prespecified procedures, including the data snapshot to use, the analyses to perform, the outputs to produce, and the people authorized to receive those outputs.

A treatment code such as A or B labels randomized groups without necessarily revealing which is the investigational treatment or control. The treatment-identity key maps those labels to named treatments. A statistician who sees A and B but not the key has treatment-coded access; a statistician who also sees the mapping has treatment-identified access. These are distinct from pooled access, where data are combined across groups so that arm-specific results are not available. The earlier material on information tiers supplies the vocabulary for describing these distinctions.

Access Is a Property of the Whole Analysis Workflow

The data view alone does not fully describe what the statistician knows. For example, coded arm-specific event counts can show that one coded group has more events, even if the statistician does not know which treatment that group received. Conversely, a pooled summary may conceal that contrast. Access planning should therefore record both the source data and the outputs that can be derived from them.

Before an interim analysis, the plan should make clear at least the following:

• Which snapshot, cutoff date, and participant records are eligible for analysis.
• Whether the statistician receives pooled summaries, separate summaries by code, or participant-level data.
• Whether the treatment-identity key is withheld, and who controls any release of it.
• Which calculations and checks the statistician must perform, and which outputs may be shared with authorized recipients.
• How the statistician’s work is kept separate from routine trial decisions and communications.

These specifications prevent a common ambiguity: a protocol may say that an analysis is “blinded” even though the statistician receives separate coded groups. The codes conceal treatment names, but the group-specific results remain visible. Such an arrangement may be appropriate for a particular duty; it is not equivalent to giving the statistician only a pooled summary.

Match Information to the Assigned Analysis

The least informative access arrangement is not automatically the safest or the best. If the statistician must estimate a quantity that depends on differences between coded groups, pooled data may be insufficient. If the statistician only needs a pooled nuisance estimate, arm-specific information or the treatment key may be unnecessary. The access plan should justify the information required by the calculation rather than treating “more blinded” or “more unblinded” as universal goals.

For instance, a variance calculation from separate coded groups can use the group sample sizes and sample variances while still withholding treatment names. This is different from estimating variability after combining all observations without regard to group. The following arithmetic illustrates the data dependence; it does not imply that any particular trial should use this estimate for an adaptation.

Why the Identity Key Changes Interpretation

With two treatment codes, the identity key determines which named treatment corresponds to each coded group. The algebra shows exactly what changes when the key is absent. Let \(D=\bar{x}_A-\bar{x}_B\) be a coded mean difference. If the code labels are swapped, the difference becomes \(\bar{x}_B-\bar{x}_A=-D\). Thus, without the mapping, the sign identifies a direction between codes, not a direction between named treatments.

This is a simple but important justification for separating access to coded data from access to the key. The statistician can perform some calculations without knowing treatment names, but cannot attach named-treatment interpretation to code-specific results without the mapping. In a multi-arm trial, the same issue applies to each code: knowing several coded results does not by itself reveal which result belongs to a named treatment.

Separation, Checks, and Common Failure Modes

An access plan is only effective if the data route, analysis work, and communications follow it. Useful checks include confirming that the snapshot contains the prespecified cutoff and eligible records; comparing input counts with the planned data extract; verifying code labels against the authorized source; and checking that output tables contain only the fields intended for their recipients. A mismatch in participant counts, an unexplained code change, or a report that includes a named-treatment contrast when only coded results were authorized should be investigated before any result is circulated.

The statistician should also be able to identify what is not known. If the identity key is withheld, the analysis record should not infer treatment identity from code ordering, outcome patterns, or informal messages. If the key is available, the record should reflect that the analysis is treatment-identified rather than describe it as merely coded. Access logs, controlled transfer of snapshots, and review of output recipients can help detect whether the intended separation has failed.

A frequent mistake is to reason, “The statistician sees only A and B, so the analysis is blinded and the trial team cannot be affected.” The correction is that coded arm-specific results still reveal between-code patterns to the statistician, and the codes might be linked to named treatments through the key or other disclosures. Whether this is acceptable depends on the assigned duty and safeguards; the word “coded” alone does not establish that no interim information is available or that no information can be passed onward.

These are access arrangements, not rankings of quality. A statistician with only pooled data may be unable to perform an assigned arm-specific calculation. A statistician with identified data may be able to perform the required analysis but could also produce or disclose results beyond the authorized purpose. In either case, the plan must specify the duty, necessary inputs, and permitted outputs.

The arrangement also has limits. Procedures cannot guarantee that a recipient will never infer treatment identity from an unusual pattern, and a firewall cannot correct inaccurate or incomplete interim data. Independence is not a substitute for data-quality checks, clear analysis specifications, or documented authorization. If the duties change, the access plan and safeguards should be reviewed rather than assuming that the original access remains sufficient.